Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • E-4031: Benchmark hERG Potassium Channel Blocker for Card...

    2026-04-10

    E-4031: Benchmark hERG Potassium Channel Blocker for Cardiac Electrophysiology Research

    Executive Summary: E-4031 (APExBIO, SKU B6077) is a potent, selective ATP-sensitive potassium channel inhibitor with an IC50 of 7.7 nM for the hERG channel, playing a critical role in cardiac action potential modulation (APExBIO product page). The compound is widely used for benchmarking cardiac electrophysiology assays and modeling drug-induced arrhythmias, including early afterdepolarizations (EADs) and torsades de pointes (TdP) (Sanguinetti et al., 1995, DOI). QT interval prolongation and IKr current blockade by E-4031 are reproducible in both in vitro and in vivo models (Varró et al., 1999, DOI). E-4031’s high purity and chemical stability underpin its use in preclinical drug safety workflows (APExBIO). Its selectivity and robust reproducibility make it essential for cardiac repolarization and proarrhythmic risk studies.

    Biological Rationale

    The hERG (human Ether-à-go-go-Related Gene) potassium channel conducts the rapid delayed rectifier potassium current (IKr), a principal determinant of phase 3 repolarization in cardiac myocytes (Varró et al., 1999). ATP-sensitive potassium channels are present in the myocardium, pancreas, and brain, linking metabolic state to membrane excitability. Modulation of these channels affects cardiac action potential duration, refractoriness, and arrhythmia susceptibility. Pharmacological inhibition of IKr is a validated strategy for modeling acquired long QT syndrome and for preclinical proarrhythmic risk assessment. E-4031, as a selective hERG channel blocker, is used to probe the molecular basis of cardiac repolarization and to assess the liability of new drug candidates to induce QT prolongation and torsades de pointes (TdP).

    Mechanism of Action of E-4031

    E-4031 binds selectively to the open and inactivated states of the hERG potassium channel, inhibiting IKr with an IC50 of 7.7 nM at 37°C and physiological ionic strength (APExBIO). This blockade delays phase 3 repolarization, thereby prolonging cardiac action potential duration (APD) and the QT interval on the electrocardiogram. In vitro, E-4031 induces early afterdepolarizations (EADs), reduces upstroke velocity, and slows diastolic depolarization rate. In vivo, administration of E-4031 in animal models results in dose-dependent QT and activation-recovery interval (ARI) prolongation, with pronounced effects in the mid-myocardium especially during bradycardia (Varró et al., 1999). The compound does not alter sodium or L-type calcium currents at relevant concentrations, supporting its selectivity for hERG/IKr.

    Evidence & Benchmarks

    • E-4031 inhibits hERG/IKr current with an IC50 of 7.7 nM in heterologous expression systems (Sanguinetti et al., 1995, DOI).
    • In isolated ventricular myocytes, E-4031 prolongs action potential duration (APD90) in a concentration-dependent manner (Varró et al., 1999, DOI).
    • In vivo, E-4031 administration produces QT interval prolongation and increases proarrhythmic risk in animal models (Hondeghem et al., 2001, DOI).
    • APExBIO E-4031 (B6077) is supplied at ≥98% purity, confirmed via HPLC and NMR, enabling reliable, reproducible results (APExBIO).
    • E-4031 is insoluble in water but dissolves at ≥103 mg/mL in DMSO and ≥9.66 mg/mL in ethanol with gentle warming, facilitating flexible assay design (APExBIO).

    Compared to prior reviews such as E-4031 in 3D Cardiac Electrophysiology, which focuses on organoid modeling, this article provides a comprehensive, citation-rich overview of E-4031’s validated pharmacological benchmarks and its essential role in proarrhythmic risk prediction.

    Applications, Limits & Misconceptions

    E-4031 is used as a gold-standard tool for:

    • Benchmarking in vitro and in vivo cardiac electrophysiology assays.
    • Assessing drug-induced QT interval prolongation risk.
    • Inducing and studying early afterdepolarizations (EADs) and torsades de pointes (TdP) in preclinical models.
    • Validating new cardiac safety pharmacology workflows.
    • Proarrhythmic substrate modeling in translational research (Mechanistic Insights and Next-Generation Applicat... extends this article by exploring molecular mechanisms underlying E-4031’s selectivity).

    Common Pitfalls or Misconceptions

    • Not a therapeutic drug: E-4031 is not approved for clinical use in humans and is strictly for laboratory research.
    • Water insolubility: Direct dissolution in aqueous buffers is ineffective; use DMSO or ethanol as solvents, per APExBIO guidance.
    • Nonselectivity at high concentrations: Supra-physiological doses may affect other ion channels; always use within validated concentration ranges.
    • Not a universal arrhythmia model: E-4031 specifically models long QT and TdP but does not replicate all arrhythmic conditions.
    • Storage requirements: Solutions are for short-term use only and must be stored at -20°C to preserve stability.

    For laboratory best practices and troubleshooting, see E-4031 (SKU B6077): Optimizing Cardiac Electrophysiology, which provides workflow and protocol optimization tips not detailed here.

    Workflow Integration & Parameters

    For robust cardiac electrophysiology studies, E-4031 is typically prepared in DMSO at ≥103 mg/mL or ethanol at ≥9.66 mg/mL with mild warming and sonication. Working aliquots should be freshly diluted into physiological buffers immediately prior to use. For in vitro patch-clamp or multi-electrode array (MEA) assays, final working concentrations range from 1 nM to 1 μM, depending on the model and endpoint (Sanguinetti et al., 1995). In vivo dosing regimens must be determined based on species, route, and desired QT prolongation. All solutions should be used within 24 h and stored at -20°C if not immediately deployed. APExBIO’s high-purity E-4031 (B6077) is supported by HPLC and NMR quality control data for reproducibility.

    This article updates and consolidates key workflow parameters beyond those addressed in E-4031 (SKU B6077): Precision hERG Blockade for Cardiac Electrophysiology, which focuses on assay reproducibility and data interpretation strategies.

    Conclusion & Outlook

    E-4031 remains the benchmark selective hERG/IKr channel inhibitor for preclinical cardiac repolarization and proarrhythmic risk modeling. Its quantitative, reproducible effects on action potential duration, QT interval, and arrhythmogenic risk underpin its widespread use in drug discovery and cardiac safety research. As advanced 3D cardiac models and high-content screening platforms evolve, E-4031 will continue to provide critical reference data for translational and regulatory workflows. For validated, quality-assured supply, APExBIO’s E-4031 (B6077) remains the gold standard for research applications.